Can I Take St. John's Wort with Cytomel (Liothyronine)?

What Is the Interaction Between St. John's Wort and Liothyronine?

St. John's Wort reduces the effective circulating level of liothyronine by speeding up its breakdown and limiting its absorption from the gut. The herb's active constituents, hyperforin in particular, are potent inducers of the nuclear pregnane X receptor (PXR), which upregulates CYP3A4, CYP2C9, and the drug efflux transporter P-glycoprotein (P-gp) in intestinal epithelium and hepatocytes. These three pathways collectively increase first-pass metabolism and efflux of many orally administered drugs, including thyroid hormones.

A 2004 review in the British Journal of Clinical Pharmacology catalogued more than 30 drug classes whose plasma concentrations fall measurably after St. John's Wort co-administration, attributing the effect primarily to hyperforin-driven PXR activation and CYP3A4 induction [1]. Although most of the studied drugs are not thyroid hormones, the enzyme pathways involved overlap substantially with those responsible for peripheral T3 metabolism and enterohepatic recirculation.

Pharmacokinetic Pathway: CYP3A4 and Hepatic Clearance

CYP3A4 is expressed at high levels in both the liver and the small intestine. Liothyronine undergoes conjugation and deiodination in hepatic tissue, and induction of CYP-related sulfotransferase and glucuronosyltransferase activity accelerates these reactions. A study in Clinical Pharmacokinetics confirmed that hyperforin concentrations achievable with standard St. John's Wort doses (900 mg/day standardized to 5% hyperforin) produce CYP3A4 induction comparable to rifampin in some metabolic pathways [2]. When hepatic clearance of T3 increases, the dose of liothyronine that was previously therapeutic may no longer maintain euthyroid free T3 levels.

Pharmacokinetic Pathway: P-glycoprotein and Gut Absorption

P-gp acts as an efflux pump at the brush border of intestinal epithelium, transporting absorbed molecules back into the gut lumen before they reach the portal circulation. A study published in Drug Metabolism and Disposition demonstrated that St. John's Wort upregulates intestinal MDR1 (the gene encoding P-gp) by roughly 1.4-fold after 14 days of administration [3]. Thyroid hormones are known P-gp substrates [4]. Reduced net absorption from each oral liothyronine dose compounds the hepatic clearance effect.

Pharmacodynamic Considerations

There is no direct antagonism between hypericin and T3 receptor binding. The interaction is entirely pharmacokinetic. That distinction matters clinically: the patient does not feel the herb "blocking" thyroid hormone the way a receptor antagonist would. Instead, symptoms of under-replacement return gradually, which makes the connection to a new supplement easy to miss.

Why Liothyronine Is More Vulnerable Than Levothyroxine

Liothyronine and levothyroxine are both subject to the same induction mechanisms, but liothyronine's pharmacokinetic profile makes the consequences more abrupt.

Short Half-Life Leaves No Buffer

Levothyroxine (T4) has a half-life of approximately 7 days. Free T4 serum levels decline slowly after any change in absorption or clearance, giving clinicians a wider window to detect and correct the problem. Liothyronine has a half-life of only 1-2 days [5]. A meaningful drop in free T3 can therefore appear within 48-72 hours of starting an inducer like St. John's Wort. Patients on combination T4/T3 therapy or on liothyronine monotherapy may notice hypothyroid symptoms within days rather than weeks.

Narrow Therapeutic Index

The American Thyroid Association 2014 guidelines on hypothyroidism management note that even modest deviations from target free T3 concentrations produce measurable changes in cardiac rate, thermogenesis, and CNS function [6]. Because the therapeutic window for liothyronine is narrow, a 20-30% reduction in bioavailability driven by enzyme induction is not a minor perturbation. It is clinically relevant.

TSH Is a Lagging Indicator for T3 Monitoring

When a patient takes liothyronine, serum TSH is suppressed to low or undetectable levels even at physiologic replacement doses, because exogenous T3 directly suppresses pituitary thyrotropin. A rise in TSH therefore lags behind the actual fall in free T3 by days to weeks. Clinicians must measure free T3 directly, not rely on TSH alone, when evaluating a suspected St. John's Wort interaction [6].

Clinical Evidence: What the Data Actually Show

No randomized controlled trial has studied St. John's Wort specifically in liothyronine-treated patients. The evidence base is mechanistic and extrapolated from better-characterized drug interactions.

Levothyroxine Interaction Data

A 2007 case series in Thyroid reported three patients on stable levothyroxine therapy who developed rising TSH and symptomatic hypothyroidism after beginning St. John's Wort supplementation; TSH normalized within 6-8 weeks of stopping the herb [7]. Because liothyronine is pharmacologically downstream of T4 and uses the same elimination pathways, the same induction mechanism applies. The liothyronine risk is considered at least equivalent.

Broader CYP3A4/P-gp Interaction Database Evidence

The FDA drug interaction guidance for industry identifies St. John's Wort as a "strong clinical inducer" in the CYP3A4 category, noting that co-administration with sensitive CYP3A4 substrates reduces their AUC by more than 80% in some cases [8]. The FDA label for Cytomel (liothyronine sodium tablets) does not specify St. John's Wort by name, but the label warns that "drugs that increase biliary excretion or induction of hepatic metabolizing enzymes can decrease T3 levels" [9]. St. John's Wort meets both conditions.

Natural Medicines Database Rating

The Natural Medicines Comprehensive Database (Therapeutic Research Center) rates the St. John's Wort and thyroid hormone interaction as "Moderate" with a recommendation to avoid concurrent use unless monitored. This rating reflects mechanistic plausibility plus case-level clinical evidence, consistent with how the interaction is classified in most clinical pharmacology references.

HealthRX Clinical Decision Framework: St. John's Wort + Liothyronine

The following tiered assessment is used by the HealthRX medical team when patients report combining these two agents:

Tier 1 (Low urgency, no symptoms): Patient started St. John's Wort less than 7 days ago and free T3 has not yet been rechecked. Action: discontinue St. John's Wort, schedule free T3 recheck in 4 weeks.

Tier 2 (Moderate urgency, mild symptoms): Patient reports fatigue, cold intolerance, or mild weight gain. Free T3 drawn and compared to baseline. Action: hold St. John's Wort immediately, recheck free T3 and TSH in 2-3 weeks, consider temporary 10-15% dose increase of liothyronine if free T3 is confirmed below target range.

Tier 3 (High urgency, significant symptoms or confirmed lab decline): Free T3 dropped more than 25% below baseline or patient reports severe fatigue, constipation, bradycardia, or pitting edema. Action: urgent prescriber contact within 24-48 hours; hold St. John's Wort; dose adjustment of liothyronine guided by repeat free T3 at 2-week intervals until stable.

Mechanism Summary: How St. John's Wort Lowers T3

Understanding the mechanism helps patients and clinicians recognize why the interaction is not immediate on day one but becomes clinically apparent over 7-21 days.

Step 1: PXR Activation by Hyperforin

Hyperforin binds PXR within hours of ingestion. PXR then translocates to the nucleus and upregulates transcription of CYP3A4, CYP2C9, UGT1A1, and MDR1 (P-gp). This transcriptional upregulation takes 5-14 days to reach maximal enzyme expression [1].

Step 2: Increased First-Pass Metabolism

As intestinal CYP3A4 and P-gp rise, a greater fraction of each liothyronine dose is either metabolized before reaching the portal vein or pumped back into the gut lumen. The net absorbed dose falls below what was previously calibrated as therapeutic.

Step 3: Accelerated Hepatic Conjugation

Hepatic UGT and sulfotransferase activity, also upregulated by PXR, accelerates glucuronidation and sulfation of T3 in the liver. These conjugated metabolites are excreted in bile and do not contribute to circulating free T3 [4]. A 2003 paper in Endocrinology confirmed that hepatic conjugation is a quantitatively significant route of T3 inactivation and that enzyme induction increases this pathway measurably [10].

Step 4: Symptomatic Hypothyroidism

Free T3 falls. Because liothyronine's half-life is only 1-2 days, the decline happens quickly. Within 3-10 days of maximal induction, patients on a previously stable liothyronine dose may experience fatigue, increased cold sensitivity, constipation, slowed cognition, dry skin, or weight gain. These are the cardinal signs of hypothyroidism and should prompt immediate lab assessment and prescriber contact.

What to Do If You Are Already Taking Both

Do not stop liothyronine abruptly. Abrupt discontinuation can worsen hypothyroidism severely.

If you started St. John's Wort recently (less than 14 days ago): Contact your prescriber and stop the herb. Request a free T3 and TSH measurement within 2-4 weeks to confirm your levels have remained stable.

If you have been taking both for weeks or months: Your prescriber may have already adjusted your liothyronine dose upward to compensate, knowingly or not. Do not stop St. John's Wort abruptly either, because rapid withdrawal of enzyme induction will cause free T3 to rise as your original dose becomes over-replacement again. Taper off St. John's Wort over 2-4 weeks with free T3 monitoring every 2 weeks.

Dose adjustment guidance: The American Association of Clinical Endocrinology (AACE) 2022 clinical practice guidelines on hypothyroidism advise that any change in a patient's medication or supplement regimen that is known to affect thyroid hormone absorption or metabolism should trigger TSH and free thyroid hormone measurement within 4-6 weeks [11]. For liothyronine specifically, free T3 is the primary endpoint.

Monitoring Protocol for Patients on Liothyronine

Patients taking liothyronine require more frequent monitoring than those on levothyroxine alone, even without supplements, because of the short half-life and direct T3 suppression of TSH.

Recommended Lab Panel

• Free T3: Primary endpoint. Target range varies by individual; typically 3.1-4.4 pg/mL in most clinical guidelines, but confirm target with your prescriber [6].
• Free T4: Useful if the patient is on combination therapy.
• TSH: Useful to detect over-replacement (suppressed TSH); less useful acutely to detect under-replacement when free T3 is the active variable.
• Timing: Draw labs in the morning, at least 4-6 hours after the last liothyronine dose, to avoid peak-level interference.

Symptom Diary

Patients should track energy level, resting heart rate, body temperature, and bowel frequency. A change in any two of these within 2 weeks of starting St. John's Wort is a signal to draw labs and call the prescriber rather than wait for the next scheduled appointment. Early intervention prevents the need for more significant dose adjustments later.

Safer Alternatives to St. John's Wort for Patients on Liothyronine

St. John's Wort is most commonly self-prescribed for mild to moderate depression. Several alternatives carry less interaction risk for patients on thyroid hormone replacement.

Pharmacological Alternatives

SSRIs such as sertraline (Zoloft) and escitalopram (Lexapro) are first-line treatments for depression per the American Psychiatric Association Practice Guidelines. Neither is a CYP3A4 inducer, and neither has a documented pharmacokinetic interaction with liothyronine at standard doses [12]. Patients with hypothyroid-associated depression should also ensure their free T3 is in the optimal part of the reference range before adding any antidepressant, as under-replaced hypothyroidism itself produces depressive symptoms.

Supplement Alternatives With Lower Interaction Risk

Saffron extract (Crocus sativus, 30 mg/day) has demonstrated antidepressant effects comparable to fluoxetine in two small randomized trials [13] and does not appear to induce CYP3A4 or P-gp. Magnesium glycinate (310-420 mg/day) may support mood and sleep quality without enzyme induction; a 2017 randomized trial (N=126) in PLOS ONE reported significant reduction in depression and anxiety scores over 6 weeks [14]. Neither saffron nor magnesium eliminates all interaction risk across all drugs, so disclosure to your prescriber remains necessary.

Talking to Your Prescriber: What to Say

Many patients hesitate to mention herbal supplements to their physicians. A 2017 survey published in JAMA Internal Medicine found that 69% of supplement users did not disclose their use to a clinician [15]. For patients on liothyronine, non-disclosure is particularly risky given how quickly T3 levels can shift.

Tell your prescriber: "I have been taking [dose] of St. John's Wort for [duration]. I want to make sure my liothyronine dose is still correct." This single sentence triggers the appropriate clinical response: a free T3 check, a review of your symptom history, and a dosing decision based on data rather than guesswork.

The FDA's MedWatch program allows patients to report adverse events from drug-supplement interactions at fda.gov/safety/medwatch, and doing so contributes to the post-marketing surveillance database that eventually leads to formal label warnings [8].